Campaigning is set to conclude tomorrow for the first phase of polling in Jharkhand, where 43 assembly constituencies will ...

Neurogene has a $903M market cap with two phase 1/2 assets, NGN-401 for Rett Syndrome and NGN-101 for CLN5 Batten Disease.

More than two years after a gunman shot and killed 19 students and two teachers, the new Legacy Elementary School marks a new ...

“Mice treated with 12.5 mg/kg-1 fexagratinib hardly showed any symptoms in the chronic phase of EAE.” Similarly, the therapy ...

Bechtel, the engineering, procurement and construction (EPC) contractor behind the first three planned liquefaction trains at ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

MIAMI, Nov. 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and nine months ended September 30, 2024. Highlights from the ...

Viking isn't a biotech that will need to take out a lot of debt or issue a lot of new shares to get its therapies out the door. Therefore, buying its stock won't leave you at as high of a risk of your ...

Sanofi is conducting the two-part multicenter, randomized, open-label, controlled, parallel-group study (NCT04643002) to evaluate the safety, efficacy, pharmacokinetics and biomarker data of ...

This quarter, we read out our phase 1 extension study from our Tdap program. And while our phase 1 study showed improved immunogenicity from our vaccine candidate, the results did not demonstrate ...

Q3 2024 Earnings Conference Call November 7, 2024 11:00 AM ETCompany ParticipantsKim Golodetz - Alliance Advisors ...

ADC Therapeutics has stopped development of lead solid tumor candidate ADCT-601. The biotech axed the AXL-directed ...